inra tours nouzilly

Search Reset search Search

suggestions

Val de Loire

With its research in integrative biology and sustainable management, its experimental capacities and nearly 800 staff members, including 632 permanent staff, the INRAE ​​Val de Loire centre conducts research around four axes: “Soil dynamics and environmental management” , "Integrative biology of trees and associated biodiversity for the sustainable management of forest ecosystems", "Integrative animal biology, sustainability of farming systems", "Infectiology and One Health". These areas of research are spread over four sites: Orléans, Tours, Nogent-sur-Vernisson and Bourges.

The INRAE Val de Loire centre develops generic research and integrated and multidisciplinary studies, sources of innovation for better sustainability of natural resources and agricultural and forestry systems and their associated biodiversity. Thanks to its technological platforms, analyses can be carried out at the different scales of the molecule, the individual, populations and ecosystems. Imaging now makes it possible to visualize and track physiological and pathophysiological mechanisms over time.

Spread over 1,500 hectares, the centre's experimental facilities make it possible to develop new models and study genetic, animal, plant or microbial resources to acquire particularly original data. They also open up the possibilitý to test new sustainable approaches such as the methanisation of effluents.

Download the research centre presentation pdf - 876.84 KB

All the centre's news

Our need for research has never been more urgent

01 January 2020

• Most recent

thematic Climate change and risks

Major European studies for sustainable small ruminant farming

14 March 2024

thematic Food, Global Health

European project to fight 5 infectious animal diseases

05 October 2023

INRAE and its North American partners strengthen their scientific and institutional cooperation

06 June 2023

thematic Agroecology

Persistence of pesticide residues in soils: the importance of monitoring at a national scale

24 May 2023

Soil: a world revealed

29 November 2021

• Share on Facebook
• Share on Twitter
• Share on Linkedin
• Share by email
• Share by link

link_copied

• Consulting Editors
• For authors
• Publication ethics
• Publication alerts by email
• Advertising

Advertisement

Research Article Inflammation Free access | 10.1172/JCI61667

PAR1 contributes to influenza A virus pathogenicity in mice

Khaled khoufache, 1,2 fatma berri, 1 wolfgang nacken, 3 annette b. vogel, 4,5 marie delenne, 1 eric camerer, 6,7 shaun r. coughlin, 8 peter carmeliet, 9,10 bruno lina, 1 guus f. rimmelzwaan, 11 oliver planz, 4 stephan ludwig, 3 and béatrice riteau 1,2.

1 Virologie et Pathologie Humaine, EA 4610, Université Lyon1, Faculté de Médecine RTH Laennec, Lyon, France. 2 INRA Tours, Nouzilly, France. 3 Institute of Molecular Virology, ZMBE, Westfälische-Wilhelms-University, Münster, Germany. 4 Friedrich-Loeffler-Institute, Institute of Immunology, University Hospital, Tuebingen, Germany. 5 Institute of Immunology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany. 6 INSERM U970, Paris Cardiovascular Centre, Paris, France. 7 Université Paris-Descartes, Paris, France. 8 Cardiovascular Research Institute, UCSF, San Francisco, California, USA. 9 Laboratory of Angiogenesis and Neurovascular link, Vesalius Research Center, VIB, Leuven, Belgium. 10 Laboratory of Angiogenesis and Neurovascular link, Vesalius Research Center, KU Leuven, Leuven, Belgium. 11 Department of Virology, Erasmus Medical Center, Rotterdam, the Netherlands.

Address correspondence to: Beatrice Riteau, EMR 4610 VirPath, Virologie et Pathologie Humaine, Faculté de médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, F-69008, Lyon, France. Phone: 33.1.0478771008; Fax: 33.1.0478778751; E-mail: [email protected] .

Authorship note: Khaled Khoufache and Fatma Berri contributed equally to this work.

Find articles by Khoufache, K. in: JCI | PubMed | Google Scholar

Find articles by Berri, F. in: JCI | PubMed | Google Scholar

Find articles by Nacken, W. in: JCI | PubMed | Google Scholar

Find articles by Vogel, A. in: JCI | PubMed | Google Scholar

Find articles by Delenne, M. in: JCI | PubMed | Google Scholar

Find articles by Camerer, E. in: JCI | PubMed | Google Scholar

Find articles by Coughlin, S. in: JCI | PubMed | Google Scholar

Find articles by Carmeliet, P. in: JCI | PubMed | Google Scholar

Find articles by Lina, B. in: JCI | PubMed | Google Scholar

Find articles by Rimmelzwaan, G. in: JCI | PubMed | Google Scholar

Find articles by Planz, O. in: JCI | PubMed | Google Scholar

Find articles by Ludwig, S. in: JCI | PubMed | Google Scholar

Find articles by Riteau, B. in: JCI | PubMed | Google Scholar

Published December 3, 2012 - More info

Influenza causes substantial morbidity and mortality, and highly pathogenic and drug-resistant strains are likely to emerge in the future. Protease-activated receptor 1 (PAR1) is a thrombin-activated receptor that contributes to inflammatory responses at mucosal surfaces. The role of PAR1 in pathogenesis of virus infections is unknown. Here, we demonstrate that PAR1 contributed to the deleterious inflammatory response after influenza virus infection in mice. Activating PAR1 by administering the agonist TFLLR-NH 2 decreased survival and increased lung inflammation after influenza infection. Importantly, both administration of a PAR1 antagonist and PAR1 deficiency protected mice from infection with influenza A viruses (IAVs). Treatment with the PAR1 agonist did not alter survival of mice deficient in plasminogen (PLG), which suggests that PLG permits and/or interacts with a PAR1 function in this model. PAR1 antagonists are in human trials for other indications. Our findings suggest that PAR1 antagonism might be explored as a treatment for influenza, including that caused by highly pathogenic H5N1 and oseltamivir-resistant H1N1 viruses.

Influenza is an ineradicable contagious disease that occurs in seasonal epidemics and sporadic pandemic outbreaks that pose significant morbidity and mortality for humans and animals ( 1 – 3 ). The continuous sporadic infections of humans with highly pathogenic avian influenza viruses of the H5N1 subtype and the recent pandemic caused by swine-origin H1N1 viruses highlight the permanent threat caused by these viruses ( 4 – 6 ). The pathogenesis of influenza A virus (IAV) infection is not fully understood, but involves both viral traits and the host immune response ( 3 ). Full understanding of the host response may aid in the development of intervention strategies that target these host factors.

Both innate and adaptive components of the immune system are activated shortly after virus infection, which provides an efficient line of defense against IAV ( 7 ). However, excessive inflammation may also result in lung damage that limits respiratory capacity and may account for IAV pathogenesis in humans ( 1 , 8 , 9 ). Recruitment of inflammatory cells to inflamed sites is controlled by a number of cellular components, including proteases ( 10 ). These proteases not only cleave extracellular substrates, but also mediate signal transduction in part via protease-activated receptors (PARs) ( 11 – 14 ). PAR1, which links local protease activity to cellular responses involved in thrombosis, inflammation, and cytoprotection ( 15 , 16 ), shows increased expression in the airways of IAV-infected mice ( 17 ). The role of PAR1 in the context of IAV infection has not been studied. We report evidence that PAR1 signaling contributed to the deleterious inflammation that followed influenza virus infection in mice in a manner dependent on plasminogen (PLG). While administration of a PAR1 agonist to mice increased severity of IAV infection, PAR1 deficiency protected mice from fatal outcome. Administration of the PAR1 antagonist SCH79797 ( 18 ) to mice decreased inflammation and improved survival after infection with multiple IAV strains, including a highly pathogenic avian H5N1 strain and 2009 pandemic H1N1 virus. Importantly, administration of SCH79797 improved survival in mice even when administered 48 or 72 hours after inoculation. PAR1 antagonists are currently in clinical trials for potential use as antithrombotic drugs ( 19 – 22 ). Because an intervention strategy aimed at a host cellular protein would be effective against virus strains that develop resistance to existing antiviral drugs, PAR1 antagonists might be explored for the treatment of IAV in additional preclinical models and, if appropriate, in humans.

PAR1 contributes to the pathogenesis of IAV infection. To investigate the role of PAR1 in the pathogenesis of IAV infection, WT mice were inoculated with 50 or 500 PFU of H1N1 strain A/PR/8/34 (referred to herein as H1N1) and either left untreated or stimulated with 50 μM of the PAR1 agonist TFLLR-NH 2 (referred to herein as PAR1-activating peptide; PAR1-AP). Mice treated with PAR1-AP displayed enhanced weight loss and higher mortality rates after infection compared with untreated control mice, differences that were statistically significant at both doses (Figure 1 A). In contrast, treatment of uninfected mice with PAR1-AP did not affect survival or body weight of mice (Figure 1 B), which indicates that the effect of PAR1-AP on survival and weight loss requires IAV infection. Moreover, treatment with a control peptide did not impair survival or increase weight loss in IAV-infected mice (Figure 1 C), militating against nonspecific effects of peptide administration. Thus, PAR1 activation led to increased pathogenicity of IAV infection.

Effect of PAR1 activation and PAR1 deficiency on IAV pathogenicity. ( A ) Time course of IAV-induced pathogenesis and death in mice in response to PAR1 stimulation. Mice were inoculated intranasally with H1N1 (50 PFU, n = 22 per group; 500 PFU, n = 18 per group) and treated with either vehicle or 50 μM PAR1-AP. ( B ) Time course of uninfected mice treated or not with 50 μM PAR1-AP ( n = 13 per group). ( C ) Mice were infected with 50 PFU H1N1 and treated with control peptide or vehicle ( n = 10 per group). Results are average percent survival or weight loss from 3 independent experiments. ( D ) Survival and weight loss of Par1 –/– mice and WT littermates after infection with 100 PFU H1N1 ( n = 12 per group). Results are average percent survival or weight loss from 2 experiments. P < 0.05, PAR1-AP vs. untreated or Par1 –/– vs. WT, Kaplan-Meier test.

To further explore the role of PAR1 in IAV pathogenesis, we investigated the consequence of PAR1 deficiency. Par1 +/– mice were intercrossed to generate WT and Par1 –/– mice, which were infected with 100 PFU H1N1, and weight loss and survival rates were monitored. Compared with WT littermates, Par1 –/– mice were more resistant to IAV infection (Figure 1 D). Thus, PAR1 contributed to death and weight loss caused by IAV infection.

PAR1-AP increases cytokine release and neutrophil recruitment in the lungs of infected mice. Because PAR1 can trigger cytokine production in endothelial and other cell types ( 14 ), we next investigated the effects of PAR1-AP in the inflammatory response induced by IAV infection. Mice infected with 50 PFU H1N1 were treated or not with 50 μM PAR1-AP, and bronchoalveolar lavages (BALs) were collected to assess the presence of cytokines and polymorphonuclear neutrophils (PMNs) in the lungs at different time points after inoculation. IAV infection resulted in increased levels of all cytokines tested (RANTES, IL-6, and KC) in a time course–dependent manner, and PAR1-AP treatment augmented this response (Figure 2 A). Similar results were obtained when the effect of PAR1 was compared with that of a control peptide (Supplemental Figure 1; supplemental material available online with this article; doi: 10.1172/JCI61667DS1 ), confirming PAR1-AP specificity. PAR1-AP treatment also increased the occurrence of BAL PMNs 24 and 48 hours after infection, but had little effect in uninfected mice (Figure 2 B). By 72 hours after infection, the PMN content of BAL in PAR1-AP–treated and control mice was not different. These results suggest that PAR1 activation can increase IAV-induced production of cytokines and increase early recruitment of neutrophils in the lungs of infected mice.

PAR1-AP increases inflammation and virus replication during 50 PFU H1N1 infection in mice. ( A ) Cytokines in the BAL of infected mice treated or not with PAR1-AP were measured by ELISA 24, 48, and 72 hours after inoculation. Data are mean ± SD from 5–11 individual animals per group from 3 experiments. ( B ) Relative PMN numbers in BAL from infected mice treated or not with PAR1-AP. PMN percentage was determined by May-Grünwald–Giemsa staining 24, 48, or 72 hours after inoculation. Results are mean ± SD from 4–5 individual mice per group from 2 individual experiments. Noninfected mice were used as control ( n = 2–4 per group). ( C ) H1N1 virus titers in the lungs at the indicated times after infection of mice treated or not with 50 μM PAR1-AP. Data are average ± SD from 3–5 individual animals per group. * P < 0.05, treated vs. untreated, Mann-Whitney test.

Virus replication in the lungs. We then investigated whether the effect of PAR1 activation on the outcome of IAV infection in mice correlates with an increase of virus production in the lungs. To this end, infectious virus titers were determined in lungs collected from mice treated with PAR1-AP (50 μM) or control peptide at different time points after inoculation. At 24 and 48 hours after inoculation, virtually no virus replication was detected (10 1 was the detection limit of the assay), but lung virus titers significantly increased after PAR1-AP treatment (Figure 2 C). No significant differences were observed 3 and 5 days after infection. These data suggest that PAR1 activation promotes an early increase in virus production in mouse lungs.

The effect of PAR1 activation on virus production, weight loss, and survival after IAV infection is PLG dependent. To decipher the mechanism by which PAR1 accelerated virus production in vivo, we performed in vitro experiments to assess the effect of PAR1 activation on virus replication in alveolar epithelial A549 cells. PAR1-AP triggered ERK phosphorylation in these cells, with a maximal effect at about 40 μM (Figure 3 A); this concentration was used in all subsequent in vitro experiments. Because proteolytic cleavage of HA is essential for IAV infectivity, and PLG promotes IAV replication through HA cleavage ( 23 , 24 ), we examined the effect of adding PLG — alone or in combination with PAR1-AP — on virus production. As expected, viral production was barely detectable in untreated A549 cultures, but was markedly increased by the addition of PLG (Figure 3 B). Importantly, addition of PAR1-AP augmented this effect 8 and 24 hours after infection. The effect of PAR1-AP was not seen when trypsin was used as an alternative protease for IAV replication (data not shown), and PAR1 signaling did not affect virus entry into cells (Supplemental Figure 2). However, inclusion of PAR1-AP appeared to increase PLG-dependent cleavage of HA. Thus, we next infected A549 cells (MOI 0.5) in the presence or absence of PLG, with or without PAR1-AP, and evaluated HA cleavage by Western blot analysis 16 hours after infection. In the absence of PLG, similar amounts of uncleaved HA (HA 0 ) accumulated in infected cells, and PAR1-AP was without effect (Figure 3 C). In the presence of PLG, in addition to HA 0 , a 25-kDa band corresponding to HA 2 was observed. Importantly, in PAR1-AP–treated cultures, the intensity of HA 2 increased and HA 0 decreased relative to that in control cultures. Thus, viral HA was cleaved in a PLG-dependent manner that was enhanced by PAR1-AP and correlated with increased viral production.

Effect of PLG and PLG deficiency on IAV production and PAR1-AP effects. ( A ) ERK phosphorylation after stimulation of A549 cells with the indicated PAR1-AP concentrations. Anti–phospho-Erk and anti-Erk antibodies were used. ( B ) Infectious virus titers in the supernatant of infected cells after stimulation with 40 μM PAR1-AP or control peptide in the presence or absence of PLG. ( C ) Noninfected (NI) or infected (INF) cells were stimulated with 40 μM PAR1-AP or control peptide in the presence or absence of PLG. After cell lysis, proteins were analyzed by Western blot for HA cleavage. ( D ) Time course of IAV-induced pathogenesis in Plg –/– and WT littermates after treatment or not with PAR1-AP ( n = 9–10 mice per group from 2 experiments). ( E ) Virus titers 48 hours after infection (50 PFU) in lungs of WT or Plg –/– mice stimulated or not with 50 μM PAR1-AP. Data are average ± SD from 5 individual animals per group from 2 experiments. * P < 0.05, treated vs. untreated, Kaplan-Meier test ( D ), Mann Whitney test ( B and E ).

PLG is an important mediator of lung inflammation ( 25 , 26 ) and is known to influence IAV virulence ( 27 , 28 ). Importantly, PLG binding to cells and activation may be controlled by PAR1 signaling ( 29 , 30 ). In combination with the findings outlined above, these observations prompted us to investigate whether the effect of PAR1 signaling on the pathogenicity of IAV infection also depends on PLG in vivo. We therefore inoculated Plg –/– mice with 50 PFU H1N1 with or without PAR1-AP treatment. In contrast to WT mice, treatment of Plg –/– mice with PAR1-AP did not increase mortality rates, weight loss, or virus titers in lungs after IAV infection (Figure 3 , D and E).

Histopathological examination showed that treatment with PAR1-AP increased cellular infiltrates in lungs from infected WT mice, but not Plg –/– mice (Supplemental Figure 3). These results suggest that PAR1 activation increased early virus production, inflammation, and pathogenicity of IAV infection in a PLG-dependent fashion. Notably, when this low 50-PFU dose was used, virtually no virus replication was detected in the lungs of WT or Plg –/– mice at the indicated time points after inoculation (Figure 3 E). Additionally, leukocyte infiltration in IAV-infected WT or Plg –/– mice was barely detectable (Supplemental Figure 3). However, when a higher virus dose was used for inoculation, leukocyte infiltration and lung virus titers of Plg –/– mice were substantially lower than those of WT mice (F. Berri, unpublished observations), which suggests that PLG promotes IAV replication and inflammation. While the finding that PAR1-AP increased PLG-dependent cleavage of HA in vitro suggests that PAR1 signaling might promote viral replication by enhancing PLG/plasmin function, our data do not exclude a PAR1-independent permissive role for PLG or PLG-independent roles for PAR1 activation in IAV infection and pathogenesis.

PAR1 antagonist protects against H1N1 and H3N2 infection. We next investigated whether pharmacological inhibition of PAR1 signaling alters the course of IAV infection. The pharmacology of PARs is not well developed, and inhibitors capable of blocking PAR1 function in mouse models have not been well characterized with respect to off-target effects. Nonetheless, SCH79797 has been used to probe PAR1 function in rodent models ( 31 – 33 ); thus, encouraged by the protection against IAV seen in Par1 –/– mice, we examined the effects of this compound on the course of IAV infection. SCH79797 inhibited PAR1-AP–induced ERK activation in mouse NIH3T3 cells (Figure 4 A), which suggests that it is capable of blocking signaling by the mouse homolog of PAR1. SCH79797 treatment prevented decreased survival and increased weight loss associated with administration of PAR1-AP to IAV-infected mice (Figure 4 B). More strikingly, when mice were infected with lethal doses of H1N1 (500 and 5,000 PFU), SCH79797 treatment protected mice from weight loss and death: 47% and 16% survival, respectively, was observed in untreated control mice, whereas 84%–94% of SCH79797-treated mice survived the infections (Figure 4 C). Moreover, when SCH79797 was administered beginning 2 or 3 days after infection, mice were also significantly protected from H1N1 and from H3N2 strain A/Hong-Kong/68 (referred to herein as H3N2; Figure 4 , D and E). Treatment of uninfected mice with SCH79797 did not affect their survival rates or body weight (Supplemental Figure 4), which suggests that PAR1 antagonists do not cause side effects. Thus, SCH79797 treatment protected mice from IAV infection, consistent with the notion that PAR1 contributes to IAV pathogenesis in this model.

PAR1 antagonist protects mice against infection with H1N1 and H3N2. ( A ) Treatment of NIH3T3 cells with SCH79797 blocked ERK activation by 10 μM PAR1-AP. ( B ) SCH79797 treatment prevented PAR1-AP–induced mouse mortality in a dose-dependent manner. ( C ) IAV-induced pathogenesis in infected mice treated or not with SCH79797. Mice were inoculated with 500 PFU ( n = 17–19 per group) or 5,000 PFU ( n = 14 per group) H1N1 and treated or not with 50 μM SCH79797 on days 0–2 after infection. ( D ) SCH79797 treatment on days 2–4 after infection with 5,000 PFU H1N1 ( n = 12 per group) or 100 PFU H3N2 ( n = 7 per group). ( E ) SCH79797 treatment on days 3–5 after infection with 5,000 PFU H1N1 ( n = 7 per group) or 100 PFU H3N2 ( n = 7 per group). * P < 0.05, treated vs. control, Kaplan-Meier test.

Inflammation and virus replication are attenuated by SCH79797. Since PAR1 activation promoted inflammation in the lungs during IAV infection, we determined whether blockade of PAR1 signaling would result in reduced IAV-induced inflammation in vivo. Mice were infected with 500 PFU H1N1 and treated or not with SCH79797, and BAL was collected at different times after inoculation. SCH79797 treatment significantly reduced the levels of RANTES, IL-6, and KC in BAL 24, 48, and 72 hours after inoculation, as measured by ELISA (Figure 5 A). 5 days after inoculation, cytokine levels were still high in the BAL from untreated mice, but barely detectable in the BAL from SCH79797-treated mice (Supplemental Figure 5). SCH79797 treatment also significantly decreased PMN frequency in the BAL of infected mice: 24 and 48 hours after inoculation, PMNs were hardly detectable in the BAL of SCH79797-treated mice, whereas they represented 10% of cells in BAL from untreated mice (Figure 5 B). Accordingly, histopathological examination revealed a reduction of cell infiltration in the lungs of infected mice treated with SCH79797 (Supplemental Figure 6).

PAR1 antagonist inhibits lung inflammation and virus replication. ( A ) Cytokines in the BAL of infected mice treated or not with SCH79797 were measured by ELISA 24, 48, and 72 hours after inoculation. Data are average ± SD from 7–11 individual animals per group, representative of 3 experiments. ( B ) Relative PMN frequency in BAL from infected mice treated or not with SCH79797. PMN percentage was determined by May-Grünwald–Giemsa staining 24, 48, and 72 hours after inoculation. Data are average ± SD from 3–5 individual mice per group. Noninfected mice were used as control ( n = 3–5 per group). Results are representative of 2 individual experiments. ( C ) Virus titers in lungs of infected mice at the indicated times after infection with 500 PFU H1N1 and treatment with SCH79797. Data are average ± SD from 3–5 individual animals per group. * P < 0.05, treated vs. control, Mann-Whitney test.

Finally, a reduction in lung virus titers was observed 24 and 48 hours after 500 PFU H1N1 inoculation compared with untreated controls (Figure 5 C). At day 3 after inoculation, lung virus titers were similar in SCH79797-treated and untreated mice (approximately 10 4 PFU/ml), which suggests that SCH79797 delayed, but did not prevent, virus production. Lung virus titers dropped to less than 10 2 PFU/ml at days 5 and 7 in both SCH79797-treated and control mice (Figure 5 C). The observation that SCH79797 suppressed markers of inflammation, but not viral titers, at day 3 suggests that inhibition of PAR1 signaling may inhibit inflammation and early virus replication by at least partially independent mechanisms.

SCH79797 protects against highly pathogenic H1N1v and H5N1 infection. To test whether inhibition of PAR1 signaling by SCH79797 also affects infection with other IAV strains, mice were infected with a highly pathogenic H5N1 strain or a pandemic H1N1v strain that had acquired oseltamivir resistance during treatment of a severe infection (see Methods and ref. 34 ), then treated or not with SCH79797. After lethal infection with 5,000 PFU H5N1 and 500 PFU H1N1v, 60% and 100% of untreated control mice died, respectively, whereas almost full protection was observed in SCH79797-treated animals of both inoculation groups ( P < 0.05; Figure 6 , A and B). In addition to mortality and body weight, the onset of clinical signs was also inhibited when H5N1-infected mice were treated with SCH79797 compared with untreated mice (data not shown). Mouse mortality was monitored until day 21 after inoculation, and sustained survival was observed after SCH79797 treatment (data not shown), which indicated that SCH79797 protection was durable. Thus, inhibition of PAR1 signaling protected mice against infection with various IAVs, including highly pathogenic strains.

PAR1 antagonist protects mice from lethal infection with H5N1 or H1N1v. Mice were inoculated intranasally with ( A ) 5,000 PFU H5N1 ( n = 10 per group) or ( B ) 500 PFU H1N1v ( n = 10–11 per group) and treated or not with 50 μM SCH79797. Results are expressed as percent survival or weight loss from 2 experiments. * P < 0.05, treated vs. control, Kaplan-Meier test.

Our present findings support an important role for PAR1 in mouse models of IAV infection. Studies with PAR1-AP indicated that PAR1 activation increased inflammation, early virus production, weight loss, and mortality after infection (Figures 1 and 2 ), and studies using Par1 –/– mice indicated that PAR1 contributed to the pathogenesis of IAV infection (Figure 1 ). The observation that SCH79797, a drug that inhibits PAR1 signaling, decreased inflammation, early virus production, weight loss, and mortality after infection was in accord with the PAR1-AP and Par1 –/– results. Moreover, the observation that SCH79797 decreased mortality after infection with multiple IAV strains (H1N1, H3N2, and H5N1), and was effective even when dosing was initiated at day 3 after inoculation, suggests that PAR1 inhibition should be explored in additional preclinical studies and, if appropriate, in humans as a possible treatment for influenza.

To our knowledge, a role for PAR1 in the response to, and the pathogenesis of, virus infections has not been previously described. PAR1 activation in endothelial cells, fibroblasts, and other cell types triggers various responses, many of which are proinflammatory (e.g., chemokine and cytokine production, adhesion molecule display, prostaglandin production, and permeability increases; refs. 14 , 15 ). In accord with our observations, intratracheal delivery of PAR1 agonist was not sufficient to trigger inflammation in the lungs of otherwise normal mice ( 35 ), but did exacerbate ventilation injury–induced pulmonary edema ( 36 ). Additionally, Par1 –/– mice are protected from ventilation injury–induced and bleomycin-induced lung injury ( 36 – 38 ). Like our results, these observations suggest that PAR1 signaling contributes to inflammatory responses to injury in the lung, the major target in our IAV infection model.

PAR1 activation did not exacerbate the effects of IAV infection in Plg –/– mice (Figure 3 ). It is possible that PLG is simply playing a permissive role for the effect of PAR1 activation in IAV infection; that is, PLG supports infection and injury, and PAR1 activation exacerbates their effects. Interestingly, however, PAR1-AP did promote PLG-dependent HA cleavage in lung epithelial cultures, suggestive of a possible interaction of PAR1 signaling with the ability of IAV to become infectious and hence replicate. These findings are consistent with the prior observation that PLG contributes to the pathogenesis of IAV infection ( 27 , 28 ). Additionally, PAR1 signaling may promote PLG activation to plasmin ( 29 , 30 ), thereby providing a possible link to increased HA cleavage and IAV production. It is also possible that PAR1 activation contributes to proinflammatory functions of PLG ( 25 , 39 – 41 ), by promoting its conversion to plasmin or by other mechanisms.

Additional considerations suggest that PAR1 activation’s abilities to promote early virus replication and to enhance a harmful inflammatory response in the respiratory tract are, at least in part, independent of each other. When PAR1-AP was delivered 3 days after infection, despite similar virus replication in the lungs, treatment still had a deleterious effect (data not shown). Additionally, based on critical residues in HA involved for cleavage by plasmin, it is unlikely that the replication of highly pathogenic H5N1 and 2009 pandemic H1N1 are modulated by plasmin ( 42 ), yet SCH79797 treatment still decreased mortality.

As noted above, we found that in IAV-infected A549 cells, activation of PAR1 increased PLG-dependent HA cleavage, an essential step for virus infectivity. Indeed, only the cleaved form of HA permits pH-dependent fusion of the viral envelope within the endosomal membranes and subsequent release of the genome into the cytosol and virus replication. In vivo, PAR1 also promoted virus replication shortly after infection. However, at 48 hours after infection, no difference in lung virus titers was observed between PAR1-AP–stimulated and unstimulated mice, which suggests that HA cleavage could be compensated by other proteases that are either recruited or activated by infection in the lungs.

Therefore, we propose a model (Figure 7 ) in which PAR1 promotes activation of PLG into plasmin. Subsequently, plasmin acts on virus replication through HA cleavage, enhancement of which likely enhances inflammation via pathogen-associated molecular patterns. Simultaneously, plasmin also acts as a proinflammatory mediator that accounts for the deleterious lung inflammation. Additionally, PAR1 triggers a variety of proinflammatory responses, independent of PLG and virus, that may exacerbate inflammation and injury. Because PAR1 couples coagulation to inflammation ( 14 , 15 ) and coagulation to fibrinolysis ( 30 ), further studies are needed to investigate the overall impact of hemostasis dysregulation in PAR1-mediated inflammation during IAV infection.

Proposed model for PAR1-mediated influenza virus pathogenesis. During IAV infection, PAR1 is activated and increases conversion of PLG into plasmin. On the one hand, plasmin cleaves and activates the viral HA, promoting IAV replication, which contributes to inflammation. On the other hand, plasmin directly promotes inflammation, and PAR1 promotes inflammation via mechanisms that are independent of PLG and virus. These likely interact with other host responses to viral infection to exacerbate inflammation and injury.

Our observation that a PAR1 agonist ( 43 , 44 ) exacerbated the effects of IAV infection suggests that PAR1 activation is capable of promoting inflammation and tissue damage in this setting. Moreover, our observation that Par1 –/– mice and SCH79797-treated mice were protected from IAV infection suggests that PAR1 activation contributes to the pathogenesis of IAV infection and that PAR1 is endogenously activated during IAV infection. Accordingly, the natural PAR1 activator thrombin was generated in IAV-infected lungs ( 45 ), and elevated levels of PAR1 were observed in the airways of IAV-infected mice ( 17 ). It is worth noting, however, that SCH79797 is known to have off-target effects on cell proliferation and survival ( 46 , 47 ); thus, we cannot exclude PAR1-independent effect of SCH79797. However, SCH79797 was capable of inhibiting PAR1 signaling (Figure 4 A and ref. 18 ), and the concordance of our KO and inhibitor studies — and the fact that their effects were opposite from those of PAR1-AP — suggest that the effects of SCH79797 in our model could be related to its ability to block PAR1 signaling.

Besides PAR1, other PARs may be involved in the pathogenesis of IAV infection ( 48 – 50 ). Identification of the exact nature and amount of proteases present at the site of infection, and how virus strain differences alter the immune response and its interactions with PARs, may advance our understanding of the pathogenesis of IAV infection.

Current treatments for IAV infection target the viral proteins M2 and NA. These drugs suffer from a number of disadvantages, including the rapid development of resistant virus variants as a result of selective pressure, which highlights the need for new pharmacological strategies against IAV infection. Because targeting host proteins would not be subject to resistance, and because severe infections with IAV are associated with a deleterious host inflammatory response, drugs regulating inflammation are appealing as potential treatments for IAV infection ( 51 , 52 ). In our present study, blocking PAR1 signaling almost fully protected mice from a highly pathogenic, oseltamivir-resistant 2009 pandemic H1N1v virus isolated from a severely diseased oseltamivir-treated patient ( 34 ). Additionally, inhibition of PAR1 signaling up to 3 days after inoculation protected mice from a detrimental outcome of infection with various IAVs, including H1N1 and H3N2 strains. Because IAVs of the H1N1 and H3N2 subtypes are currently circulating in the human population, it is reasonable to assume that PAR1 antagonists are most likely also effective against seasonal influenza viruses. Interestingly, the PAR1 antagonist vorapaxar has been studied as a potential antithrombotic drug in approximately 40,000 patients over 3 years ( 53 , 54 ). The most serious side effect, increased incidence of intracranial bleeding, occurred mainly in patients with a history of prior stroke. In the absence of such a history, the increase in the incidence of intracranial bleeding was less than 1 per 1,000 treatment-years. Thus, short periods of PAR1 antagonism would appear to be relatively safe. This observation, in consideration with our results, suggests that PAR1 antagonism should be further explored for the treatment of IAV in additional preclinical models and, if appropriate, human studies.

Cells, virus strain, and reagents. The NIH3T3 mouse cell line was a gift from D. Décimo (INSERM U758, Lyon, France). The human alveolar type II (A549) and MDCK cell lines used in this study were obtained from ATCC and grown as previously described ( 55 ). H1N1 (strain A/PR/8/34) was obtained from the ATCC. H3N2 (strain A/Hong-Kong/2/68) was obtained from the Dutch National Influenza Centre. The strain was originally obtained from the National Institute for Biological Standards and Control (NIBSC). The highly pathogenic H5N1 avian influenza virus (strain A/mallard/Bavaria/1/2006; also known as MB1) and the pandemic H1N1v influenza virus (strain A/Nordrhein-Westfalen/173/09) were used in this study. H1N1v, isolated from a severe H1N1pdm09 case and obtained through the German National Reference Centre for Influenza of the Robert Koch Institute, had acquired oseltamivir resistance during treatment ( 34 ). H5N1 was propagated in chicken eggs for 2 days, and the other viruses were propagated in confluent MDCK cells. After 2 days, cytopathic changes were complete, and culture supernatants were harvested and cleared by low-speed centrifugation and stored at –80°C. PAR1-AP and control peptide (TFLLR-NH 2 and FTLLR-NH 2 , respectively) were purchased from Bachem. The PAR1 antagonist (SCH79797 dihydrochloride) was purchased from Axon Medchem. PLG was purchased from Sigma-Aldrich, and the following antibodies were used: monoclonal anti-HA (C102; Santa Cruz Biotechnology), monoclonal anti-tubulin (Sigma-Aldrich), and polyclonal anti-ERK and phospho-ERK (Cell Signaling Technology).

In vitro stimulation. A549 cells were preincubated for 5 minutes with 40 μM PAR1-AP or control peptide or for 1 hour with 5 μM SCH79797. Cells were then infected with H1N1 (MOI 0.001) in MEM supplemented with 0.5 μM PLG (Sigma-Aldrich) in the presence of the drug. At the indicated times after stimulation, virus titers were analyzed by classical plaque assays as performed previously, using MDCK cells ( 56 ).

Western blot analysis of ERK activation and HA cleavage. A549 or NIH3T3 cells were stimulated or not with the indicated concentrations of PAR1-AP for 5 minutes at 37°C. Where indicated, cells were preincubated for 1 hour with SCH79797. Cells were then lysed, and proteins from the lysate were analyzed by Western blot for ERK activation, as previously described ( 57 ). For the HA cleavage experiments, A549 cells were stimulated or not with 40 μM PAR1-AP and infected with IAV (MOI 0.5) for 16 hours in the presence or absence of 0.5 μM PLG. Cells were then lysed, and proteins from the lysate were analyzed by Western blot, as described previously ( 57 ).

Mice. Plg –/– mice (with a disrupted Plg gene) and their WT littermates ( 58 ) and 6-week-old C57BL/6 female mice (Charles River Laboratories) were used in this study. Par1 –/– mice (with a disrupted Par1 gene) and their WT littermates were described previously ( 59 ). Heterozygous mice were crossed, and WT and KO offspring were used. Mouse ages ranged from 5 weeks to a maximum of 4 months, since the number of mice that could be obtained was limited. Male and female mice were used in the experiments. Groups of WT and KO mice were stratified for these differences in age and gender. Polymerase chain reaction of tail-tip genomic DNA was performed ( 60 ) for determination of the absence or presence of a functional Plg or Par1 gene.

Mouse infection and treatment. Mice were anesthetized and inoculated intranasally with 25 μl of a solution containing different doses of virus in the presence or absence of 50 μM PAR1-AP, 50 μM control peptide, and/or 50 μM SCH79797. 500 μM SCH79797 was also used for blocking experiments in Figure 4 B. Intranasal treatments with PAR1-AP, control peptide, and/or SCH79797 were also repeated at days 2 and 3 after infection. Alternatively, mice were inoculated, and SCH79797 was administered on days 2–4 or days 3–5 after infection. Mice were then monitored for weight loss and mortality. For assessing virus replication, lungs were obtained from scarified mice, and infectious virus titers were determined by plaque assay as described previously ( 56 ).

Cytokine detection by ELISA and PMN recruitment. Production of the cytokines RANTES, IL-6, and KC in the lungs was determined by ELISA (R&D Systems), using BAL from mice, as previously described ( 60 ). For PMN recruitment, BAL was collected in PBS (Invitrogen) supplemented with 1 mM EDTA (Invitrogen). After cytocentrifugation, the percentage of PMNs was determined by counting a total of 500 cells per sample by microscopic examination of May-Grünwald– and Giemsa-stained cytocentrifuge slides.

Lung histology. At 3 days after virus inoculation and treatment, mice were killed, and lung tissue was harvested, fixed in 10% formaldehyde, and subsequently embedded in paraffin. Tissues were sectioned at 12 μM, and sections were examined after staining with hematoxylin and eosin for histopathological changes.

Statistics. Mann-Whitney test was used for statistical analysis of lung virus titers and cytokine ELISA results. Kaplan-Meier test was used for statistical analysis of survival rates. XLSTAT software was used to analyze differences between groups; a P value less than 0.05 was considered statistically significant.

Study approval. Experiments were performed according to recommendations of the National Commission of Animal Experiment (CNEA) and the National Committee on the Ethic Reflexion of Animal Experiments (CNREEA) in compliance with European animal welfare regulation. The protocol was approved by the committee of animal experiments of the University Claude Bernard Lyon I (permit no. BH2008-13). All animal experiments were also carried out under the authority of licence issued by “la direction des services Vétérinaires” (accreditation no. 78-114). All efforts were made to minimize suffering.

View Supplemental data

We are grateful to N. Lejal for technical assistance. This work was supported by the Agence Nationale de la Recherche (ANR; to B. Riteau); Inserm Avenir (to E. Camerer); Marie Curie actions (to E. Camerer); and Long-term structural funding—Methusalem by the Flemish government (to P. Carmeliet).

Conflict of interest: Khaled Khoufache and Béatrice Riteau have a patent concerning the use of PAR1 antagonist against influenza.

Reference information: J Clin Invest. 2013;123(1):206–214. doi:10.1172/JCI61667.

• La Gruta NL, Kedzierska K, Stambas J, Doherty PC. A question of self-preservation: immunopathology in influenza virus infection. Immunol Cell Biol. 2007;85(2):85–92. View this article via: PubMed PubMed CrossRef Google Scholar
• Bouvier NM, Palese P. The biology of influenza viruses. Vaccine. 2008;26(suppl 4):D49–D53. View this article via: PubMed CrossRef Google Scholar
• Kuiken T, Riteau B, Fouchier RA, Rimmelzwaan GF. Pathogenesis of influenza virus infections: the good, the bad and the ugly. Curr Opin Virol. 2012;2(3):276–286. View this article via: PubMed CrossRef Google Scholar
• Webby RJ, Webster RG. Are we ready for pandemic influenza? Science. 2003;302(5650):1519–1522. View this article via: PubMed CrossRef Google Scholar
• Foucault ML, Moules V, Rosa-Calatrava M, Riteau B. Role for proteases and HLA-G in the pathogenicity of influenza A viruses. J Clin Virol. 2011;51(3):155–159. View this article via: PubMed CrossRef Google Scholar
• Solorzano A, Song H, Hickman D, Perez DR. Pandemic influenza: preventing the emergence of novel strains and countermeasures to ameliorate its effects. Infect Disord Drug Targets. 2007;7(4):304–317. View this article via: PubMed CrossRef Google Scholar
• Schmolke M, Garcia-Sastre A. Evasion of innate and adaptive immune responses by influenza A virus. Cell Microbiol. 2010;12(7):873–880. View this article via: PubMed CrossRef Google Scholar
• de Jong MD, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006;12(10):1203–1207. View this article via: PubMed CrossRef Google Scholar
• Peiris JS, Cheung CY, Leung CY, Nicholls JM. Innate immune responses to influenza A H5N1: friend or foe? Trends Immunol. 2009;30(12):574–584. View this article via: PubMed CrossRef Google Scholar
• Heutinck KM, ten Berge IJ, Hack CE, Hamann J, Rowshani AT. Serine proteases of the human immune system in health and disease. Mol Immunol. 2010;47(11–12):1943–1955. View this article via: PubMed CrossRef Google Scholar
• Mackie EJ, Pagel CN, Smith R, de Niese MR, Song SJ, Pike RN. Protease-activated receptors: a means of converting extracellular proteolysis into intracellular signals. IUBMB Life. 2002;53(6):277–281. View this article via: PubMed CrossRef Google Scholar
• Hollenberg MD. Proteinase-mediated signaling: proteinase-activated receptors (PARs) and much more. Life Sci. 2003;74(2–3):237–246. View this article via: PubMed CrossRef Google Scholar
• Riteau B, de Vaureix C, Lefevre F. Trypsin increases pseudorabies virus production through activation of the ERK signalling pathway. J Gen Virol. 2006;87(pt 5):1109–1112. View this article via: PubMed CrossRef Google Scholar
• Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64(6):1057–1068. View this article via: PubMed CrossRef Google Scholar
• Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407(6801):258–264. View this article via: PubMed CrossRef Google Scholar
• Coughlin SR, Camerer E. PARticipation in inflammation. J Clin Invest. 2003;111(1):25–27. View this article via: JCI PubMed Google Scholar
• Lan RS, Stewart GA, Goldie RG, Henry PJ. Altered expression and in vivo lung function of protease-activated receptors during influenza A virus infection in mice. Am J Physiol Lung Cell Mol Physiol. 2004;286(2):L388–L398. View this article via: PubMed CrossRef Google Scholar
• Ahn HS, Foster C, Boykow G, Stamford A, Manna M, Graziano M. Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3, 2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist. Biochem Pharmacol. 2000;60(10):1425–1434. View this article via: PubMed CrossRef Google Scholar
• Goto S, Yamaguchi T, Ikeda Y, Kato K, Yamaguchi H, Jensen P. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb. 2010;17(2):156–164. View this article via: PubMed CrossRef Google Scholar
• White HD. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions. Am Heart J. 2011;161(3):450–461. View this article via: PubMed CrossRef Google Scholar
• Oestreich J. SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis. Curr Opin Investig Drugs. 2009;10(9):988–996. View this article via: PubMed Google Scholar
• Shinohara Y, Goto S, Doi M, Jensen P. Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke. J Stroke Cerebrovasc Dis. 2012;21(4):318–324. View this article via: PubMed CrossRef Google Scholar
• LeBouder F, Lina B, Rimmelzwaan GF, Riteau B. Plasminogen promotes Influenza A virus replication through an annexin II-dependent pathway in absence of neuraminidase. J Gen Virol. 2010;91(pt 11):2753–2761. View this article via: PubMed CrossRef Google Scholar
• LeBouder F, et al. Annexin II incorporated into influenza virus particles supports virus replication by converting plasminogen into plasmin. J Virol. 2008;82(14):6820–6828. View this article via: PubMed CrossRef Google Scholar
• Wygrecka M, et al. Enolase-1 promotes plasminogen-mediated recruitment of monocytes to the acutely inflamed lung. Blood. 2009;113(22):5588–5598. View this article via: PubMed CrossRef Google Scholar
• Gong Y, Hart E, Shchurin A, Hoover-Plow J. Inflammatory macrophage migration requires MMP-9 activation by plasminogen in mice. J Clin Invest. 2008;118(9):3012–3024. View this article via: JCI PubMed CrossRef Google Scholar
• Goto H, Wells K, Takada A, Kawaoka Y. Plasminogen-binding activity of neuraminidase determines the pathogenicity of influenza A virus. J Virol. 2001;75(19):9297–9301. View this article via: PubMed CrossRef Google Scholar
• Goto H, Kawaoka Y. A novel mechanism for the acquisition of virulence by a human influenza A virus. Proc Natl Acad Sci U S A. 1998;95(17):10224–10228. View this article via: PubMed CrossRef Google Scholar
• Peterson EA, Sutherland MR, Nesheim ME, Pryzdial EL. Thrombin induces endothelial cell-surface exposure of the plasminogen receptor annexin 2. J Cell Sci. 2003;116(pt 12):2399–2408. View this article via: PubMed CrossRef Google Scholar
• McEachron TA, Pawlinski R, Richards KL, Church FC, Mackman N. Protease-activated receptors mediate crosstalk between coagulation and fibrinolysis. Blood. 2010;116(23):5037–5044. View this article via: PubMed CrossRef Google Scholar
• Strande JL, Hsu A, Su J, Fu X, Gross GJ, Baker JE. SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts. Basic Res Cardiol. 2007;102(4):350–358. View this article via: PubMed CrossRef Google Scholar
• Cao C, Gao Y, Li Y, Antalis TM, Castellino FJ, Zhang L. The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b. J Clin Invest. 2010;120(6):1971–1980. View this article via: JCI PubMed CrossRef Google Scholar
• Lo HM, Chen CL, Tsai YJ, Wu PH, Wu WB. Thrombin induces cyclooxygenase-2 expression and prostaglandin E2 release via PAR1 activation and ERK1/2- and p38 MAPK-dependent pathway in murine macrophages. J Cell Biochem. 2009;108(5):1143–1152. View this article via: PubMed CrossRef Google Scholar
• Seyer R, et al. Synergistic adaptive mutations in the HA and PA lead to increased virulence of pandemic 2009 H1N1 influenza A virus in mice. J Infect Dis. 2012;205(2):262–271. View this article via: PubMed CrossRef Google Scholar
• Su X, Camerer E, Hamilton JR, Coughlin SR, Matthay MA. Protease-activated receptor-2 activation induces acute lung inflammation by neuropeptide-dependent mechanisms. J Immunol. 2005;175(4):2598–2605. View this article via: PubMed Google Scholar
• Jenkins RG, et al. Ligation of protease-activated receptor 1 enhances alpha(v)beta6 integrin-dependent TGF-beta activation and promotes acute lung injury. J Clin Invest. 2006;116(6):1606–1614. View this article via: JCI PubMed CrossRef Google Scholar
• Mercer PF, Deng X, Chambers RC. Signaling pathways involved in proteinase-activated receptor1-induced proinflammatory and profibrotic mediator release following lung injury. Ann N Y Acad Sci. 2007;1096:86–88. View this article via: PubMed CrossRef Google Scholar
• Chen D, et al. Protease-activated receptor 1 activation is necessary for monocyte chemoattractant protein 1-dependent leukocyte recruitment in vivo. J Exp Med. 2008;205(8):1739–1746. View this article via: PubMed CrossRef Google Scholar
• Busuttil SJ, Ploplis VA, Castellino FJ, Tang L, Eaton JW, Plow EF. A central role for plasminogen in the inflammatory response to biomaterials. J Thromb Haemost. 2004;2(10):1798–1805. View this article via: PubMed CrossRef Google Scholar
• Syrovets T, Tippler B, Rieks M, Simmet T. Plasmin is a potent and specific chemoattractant for human peripheral monocytes acting via a cyclic guanosine monophosphate-dependent pathway. Blood. 1997;89(12):4574–4583. View this article via: PubMed Google Scholar
• O’Connell PA, Surette AP, Liwski RS, Svenningsson P, Waisman DM. S100A10 regulates plasminogen-dependent macrophage invasion. Blood. 2010;116(7):1136–1146. View this article via: PubMed CrossRef Google Scholar
• Sun X, Tse LV, Ferguson AD, Whittaker GR. Modifications to the hemagglutinin cleavage site control the virulence of a neurotropic H1N1 influenza virus. J Virol. 2010;84(17):8683–8690. View this article via: PubMed CrossRef Google Scholar
• Zhao A, et al. Immune regulation of protease-activated receptor-1 expression in murine small intestine during Nippostrongylus brasiliensis infection. J Immunol. 2005;175(4):2563–2569. View this article via: PubMed Google Scholar
• Cunningham MA, Rondeau E, Chen X, Coughlin SR, Holdsworth SR, Tipping PG. Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis. J Exp Med. 2000;191(3):455–462. View this article via: PubMed CrossRef Google Scholar
• Keller TT, et al. Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1. Circ Res. 2006;99(11):1261–1269. View this article via: PubMed CrossRef Google Scholar
• Di Serio C, et al. Protease-activated receptor 1-selective antagonist SCH79797 inhibits cell proliferation and induces apoptosis by a protease-activated receptor 1-independent mechanism. Basic Clin Pharmacol Toxicol. 2007;101(1):63–69. View this article via: PubMed CrossRef Google Scholar
• Pawlinski R, et al. Response to letter by Strande regarding article “Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy”. Circulation. 2008;117(24):e496. . View this article via: PubMed CrossRef Google Scholar
• Khoufache K, et al. Protective role for protease-activated receptor-2 against influenza virus pathogenesis via an IFN-gamma-dependent pathway. J Immunol. 2009;182(12):7795–7802. View this article via: PubMed CrossRef Google Scholar
• Nhu QM, et al. Novel signaling interactions between proteinase-activated receptor 2 and Toll-like receptors in vitro and in vivo. Mucosal Immunol. 2010;3(1):29–39. View this article via: PubMed CrossRef Google Scholar
• Feld M, et al. Agonists of proteinase-activated receptor-2 enhance IFN-gamma-inducible effects on human monocytes: role in influenza A infection. J Immunol. 2008;180(10):6903–6910. View this article via: PubMed Google Scholar
• Garcia CC, et al. Platelet-activating factor receptor plays a role in lung injury and death caused by Influenza A in mice. PLoS Pathog. 2010;6(11):e1001171. View this article via: PubMed CrossRef Google Scholar
• Walsh KB, et al. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc Natl Acad Sci U S A. 2011;108(29):12018–12023. View this article via: PubMed CrossRef Google Scholar
• Tricoci P, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366(1):20–33. View this article via: PubMed CrossRef Google Scholar
• Morrow DA, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366(15):1404–1413. View this article via: PubMed CrossRef Google Scholar
• Riteau B, et al. Characterization of HLA-G1, -G2, -G3, and -G4 isoforms transfected in a human melanoma cell line. Transplant Proc. 2001;33(3):2360–2364. View this article via: PubMed CrossRef Google Scholar
• LeBouder F, et al. Immunosuppressive HLA-G molecule is upregulated in alveolar epithelial cells after influenza A virus infection. Hum Immunol. 2009;70(12):1016–1019. View this article via: PubMed CrossRef Google Scholar
• Riteau B, Barber DF, Long EO. Vav1 phosphorylation is induced by beta2 integrin engagement on natural killer cells upstream of actin cytoskeleton and lipid raft reorganization. J Exp Med. 2003;198(3):469–474. View this article via: PubMed CrossRef Google Scholar
• Ploplis VA, et al. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation. 1995;92(9):2585–2593. View this article via: PubMed CrossRef Google Scholar
• Griffin CT, Srinivasan Y, Zheng YW, Huang W, Coughlin SR. A role for thrombin receptor signaling in endothelial cells during embryonic development. Science. 2001;293(5535):1666–1670. View this article via: PubMed CrossRef Google Scholar
• Bernard D, et al. Costimulatory receptors in a teleost fish: typical CD28, elusive CTLA4. J Immunol. 2006;176(7):4191–4200. View this article via: PubMed Google Scholar
• Version 1 (December 3, 2012): No description
• Version 2 (January 2, 2013): No description

Article tools

• Download citation information
• Send a comment
• Terms of use
• Standard abbreviations
• Need help? Email the journal
• Article usage
• Citations to this article
• Introduction
• Supplemental material
• Acknowledgments
• Version history

Sign up for email alerts

About cookies

What is a "cookie"?

A "cookie" is a piece of information, usually small and identified by a name, which may be sent to your browser by a website you are visiting. Your web browser will store it for a period of time, and send it back to the web server each time you log on again.

Different types of cookies are placed on the sites:

• Cookies strictly necessary for the proper functioning of the site
• Cookies deposited by third party sites to improve the interactivity of the site, to collect statistics

Learn more about cookies and how they work

The different types of cookies used on this site

Cookies strictly necessary for the site to function

These cookies allow the main services of the site to function optimally.  You can technically block them using your browser settings but your experience on the site may be degraded.

Furthermore,  you have the possibility of opposing the use of audience measurement tracers strictly necessary for the functioning and current administration of the website in the cookie management window accessible via the link located in the footer of the site.

Technical cookies

Audience measurement cookies (at internet), about the at internet audience measurement tool :.

AT Internet's audience measurement tool Analytics is deployed on this site in order to obtain information on visitors' navigation and to improve its use.

The French data protection authority (CNIL) has granted an exemption to AT Internet's Web Analytics cookie. This tool is thus exempt from the collection of the Internet user's consent with regard to the deposit of analytics cookies. However, you can refuse the deposit of these cookies via the cookie management panel.

Good to know:

• The data collected are not cross-checked with other processing operations
• The deposited cookie is only used to produce anonymous statistics
• The cookie does not allow the user's navigation on other sites to be tracked.

Third party cookies to improve the interactivity of the site

This site relies on certain services provided by third parties which allow :

• to offer interactive content;
• improve usability and facilitate the sharing of content on social networks;
• view videos and animated presentations directly on our website;
• protect form entries from robots;
• monitor the performance of the site.

These third parties will collect and use your browsing data for their own purposes.

How to accept or reject cookies

When you start browsing an eZpublish site, the appearance of the "cookies" banner allows you to accept or refuse all the cookies we use. This banner will be displayed as long as you have not made a choice, even if you are browsing on another page of the site.

You can change your choices at any time by clicking on the "Cookie Management" link.

You can manage these cookies in your browser. Here are the procedures to follow: Firefox; Chrome; Explorer; Safari; Opera

For more information about the cookies we use, you can contact INRAE's Data Protection Officer by email at [email protected] or by post at :

24, chemin de Borde Rouge -Auzeville - CS52627 31326 Castanet Tolosan cedex - France

Last update: May 2021

• Bacteriology teams
• Parasitology teams
• Virology teams

Infectious Diseases and Public Health

Welcome to isp .

Situated in INRAE Val de Loire Research Center in the Loire valley, the unit « Infectious Diseases and Public Health » (ISP) is a joined research unit between INRAE and the University of Tours. ISP hosts 160 staff members, including 80 researchers, in 10 research teams and core facilities such as the International Center for Bacterial Pathogens (CIRM-BP) and the team " Imaging and infectiology ". Teams are located on the INRAE campus in Nouzilly (25 km from Tours) or the Tours faculties of Pharmacy and Medicine campus.

ISP research activities are dedicated to the understanding of the interactions taking place between the host and pathogens: host can be a human or a farm animal and pathogens are bacteria , viruses or parasites that represent threats for animal and/or human health as well as economic burden. Our research is also well in line with the “One Health” concept promoting an integrated view of the animal-human-ecosystem interface to better tackle the pathogen threat. ISP missions respond to two societal demands: prevent and cure   infectious diseases and limit drug use.

ISP concentrates a large panel of complementary expertise on pathophysiology of infectious diseases in farm animals – chickens, ruminants,  swine- or model animals, thanks to its unique environment. Indeed, ISP is close to the:

• Infectiology platform (PFIE), a bio-contained animal facility for large animals, unique in France and one of the 15 available in Europe. Together, PFIE and ISP form the “Tours Animal Heath Center”;
• Phenotyping and in/eX vivo Imaging from ANImal to Molecule ( PIXANIM ) platform: another remarkable facility able to run surgery and imaging (CT scan and NMR) on small ruminants or pigs under conditions similar to those proposed in hospitals.

At the international level, in addition to numerous collaborations established by the researchers, ISP coordinates the program  IDOH , the first European Erasmus Mundus master of Sciences teaching the One Health concept in the fight against infectious diseases.

Subscribe to news

Subscribe to the website news in order to get latest information notifications.

All fields marked with an asterisk (*) are required

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

• Advanced Search
• Journal List

Copy Number Variation and Differential Expression of a Protective Endogenous Retrovirus in Sheep

Barbara viginier.

1 UMR754 “Rétrovirus et Pathologie Comparée” INRA, Université Lyon 1, Université de Lyon, Lyon, France

2 Ecole Pratique des Hautes Etudes, Paris, France

Christine Dolmazon

Isabelle lantier.

3 INRA Centre de Tours, Nouzilly, France

Frédéric Lantier

Fabienne archer, caroline leroux, christophe terzian.

Conceived and designed the experiments: BV CT. Performed the experiments: BV CD. Analyzed the data: BV CT. Contributed reagents/materials/analysis tools: BV IL FL FA CL. Wrote the paper: BV CL CT.

The Jaagsiekte sheep retrovirus exJSRV and its endogenous counterpart enJSRV co-exist in sheep. exJSRV, a betaretrovirus, is the etiological agent of ovine pulmonary adenocarcinoma, and it has been demonstrated in vitro that an enJSRV Gag variant bearing the R-to-W amino acid change at position 21 was able to block exJSRV budding from the cells, providing a potential protective role for the host. In this work, we developed a fast mutation detection assay based on the oligo ligation assay (OLA) that permits the quantification of the relative proportions of the R21 and W21 Gag variants present in individual genomes and in cDNA obtained from normal and exJSRV-induced lung tumors. We have shown that the W21/R21 ratio is variable within and between breeds. We also describe for the first time that putative protecting enJSRV variants were expressed in alveolar type II cells (AECII), the major target of exJSRV.

Introduction

Endogenous retroviruses (ERVs) represent a class of retroviruses that are inherited through the germline of their hosts like cellular genes. ERVs represent a significant portion of the host genomes (i.e., 8% of the human genome) and are generally inactivated by point mutations and/or indels [1] . However, some of these endogenous retroviruses still encode functional retroviral proteins. Two main hypotheses have been proposed to understand the maintenance of the coding capacities of ERVs: (1) endogenous retroviral proteins are necessary for the replication of ERVs, and (2) endogenous retroviral proteins are beneficial to their hosts. Several important results have shed light on the benefit of ERV proteins to their hosts. One well-illustrated beneficial impact of ERVs concerns the protection of the host from infection by related exogenous retroviruses. Protection can occur at the entry level of exogenous retrovirus through receptor interference resulting from competition for receptor binding between the exogenous and endogenous envelopes [2] . Protection can also occur later during the replication cycle of the retrovirus, either before the integration of the retroviral genome into the host nucleus [3] or during the assembly of the retroviral particles [4] .

The enJSRV/exJSRV retroviruses in sheep represent a powerful model for the study of interactions between an ERV, its exogenous counterpart and their host. The sheep genome contains approximately 30 copies of the endogenous retrovirus enJSRV, which is highly related to the exogenous betaretrovirus exJSRV (90%–98% identity at the amino acid level), the etiological agent of ovine pulmonary adenocarcinoma [5] – [8] . Among the enJSRVs, it has been shown that the enJS56A1 provirus was able to block the release of infectious JSRV particles when co-expressed in cultured cells, illustrating a novel mechanism of retroviral interference [9] . The determinant of this blocking process resides at the level of a single residue at position 21 in the Gag precursor protein. The arginine residue at position 21 (R21) of the exJSRV Gag sequence is replaced by a tryptophan (W21) in the enJSR56A1 Gag sequence. This single change confers to enJS56A1 the ability to block the normal trafficking of JSRV particles to the plasma membrane. A complete set of enJSRV proviruses was characterized from a genomic library for the Texel breed, cloned and sequenced, revealing the presence of a second provirus containing non-synonymous mutations inducing the R->W change; this provirus was named enJSRV20 [10] . Interestingly, phylogenetic analysis strongly suggested that these two protecting proviruses became fixed in the sheep during its domestication [10] .

Nothing is known concerning the variation of W21 enJSRV between individuals and between breeds. Therefore, we screened 42 sheep genomes and quantified the presence of W21 using an approach based on the oligo ligation assay (OLA), also known as the fast mutation detection assay [11] . Moreover, one can ask if protection against sheep exJSRV infection by W21 enJSRV, which was shown in vitro , is also relevant in vivo . Hence, previous data have shown that the enJSRVs are predominantly expressed in the placenta, and exJSRV infects and replicates in AECII [8] but it has never been shown if W21 RNA is present or not in these target cells. We then quantified the relative level of the W21 variant RNAs in AECII derived from tumoral and non-tumoral lungs. Our results indicate that W21 is present at variable frequencies in the genomes of several breeds and is expressed in the lung, the target of JSRV-induced transformation. Furthermore, we observed that tumoral lung samples rarely express the W21 variant, and when expressed, that it is expressed at a low level compared to that the level in normal lung samples.

Materials and Methods

Ethics statement.

All animal experiments have been performed in compliance with our institutional and national guidelines in accordance with the European Community Council Directive 86/609/EEC. The INRA Tours ethics committee approved the experimental protocols.

Sample Collection

Forty-one DNA samples extracted from total blood have been collected from 10 ovine breeds and five inbred lines (IL) from the experimental flock maintained at the large animal facility, INRA, Tours Nouzilly France ( Table 1 ). IL 16 to 63 are inbred lines derived from the Pre-Alpes breed. Fifteen samples of total lung DNA have been prepared from 7 Manech sheep from the French Basque Region that presented with respiratory symptoms and massive tumoral lesions upon gross examination and from 8 sheep of mixed breeds from a local slaughterhouse (Corbas, France) without macroscopic pulmonary lesions. Total DNA has been extracted using the Fast DNA kit as recommended by the manufacturer (Qbiogene, France). The exJSRV statuses of the sheep have been confirmed by histopathological examination to identify tumoral lesions (Anatomy and Pathological Cytology laboratory, Hospices Civils de Lyon, Pr Françoise Thivolet-Béjui) and by PCR detection of the exJSRV genome using exJSRV-specific primers targeting the 3'end of the env gene and the LTR (primer sequences available upon request). From the same 15 sheep, total RNA has been extracted using the standard RNeasy protocol (Qiagen, France) from primary AECII derived from non-tumoral (n = 5) or tumoral (n = 7) lung tissues as previously reported (Archer et al., 2007). The derivation of primary AECII failed for 3 tissues due to the poor conditions of the tissues. For each sample, 500 ng total RNA have been reverse-transcribed into cDNAs using random hexamers and M-MLV RT (Invitrogen) according to the manufacturer’s protocol and have been analyzed by PCR to determine their exJSRV status using specific primers.

DNA and cDNA Gag Amplification

The PCRs were performed using DNAs or cDNAs and the primers enJSRV 482 ( 5'-TCCTCGCCACTACTCTTATT-3' ) and enJSRV 953 ( 5'-GGAGGGTCGCTTTTAACC-3' ) to amplify specifically the Gag region of enJSRV ( Fig. 1A ); the corresponding exJSRV region is not amplified using these same primers (not shown). The PCR reactions were performed in 50 µl volumes containing Taq polymerase buffer, 1.65 mM MgCl 2 , 200 µM each dNTP, 0.2 µM each primer, 100 to 500 ng of genomic DNA, and 1.25 U of Taq polymerase (Eurobio). The amplification conditions consisted of an initial 5 min denaturation at 95°C followed by 35 cycles of 94°C for 30 sec, 55°C for 30 sec, and 72°C for 1 min and a final extension of 10 min at 72°C. Positive and negative controls were based on PCR reactions performed using the penJS65A1 and pJS21 plasmids, which contain, respectively, enJSRV and exJSRV proviral sequences.

The W/R variant at position 21 is indicated by a star. The 470 bp amplicon is represented by a gray bar. B. Ligation products obtained from the OLA detection assay of W21 and R21 variants. The sequence of the phosphate-modified downstream oligo is indicated in italics. The upstream oligo that detected the R21 to W21 mutation is labeled with HEX, whereas the two FAM-labeled oligos detected the R21 variant. Probes that were mismatched to the target by a single nucleotide at their junctions were not ligated. The ligation products were discriminated by size (60 nt for W21 coding sequence vs. 64 nt for R21 coding sequences) and color (HEX for W21 vs. FAM for R21). The W and R codons are underlined.

OLA is a genotypic assay for the detection of known mutations based on the covalent joining of two adjacent oligonucleotides by a DNA ligase when they are hybridized to a DNA target [10] . For each reaction, 4 µl of purified amplicon, 4 U of thermostable Thermus aquaticus ligase (New England Biolabs, Beverly, MA), 5 nM upstream HEX or FAM-modified oligonucleotides (HEX-GCATATGTTATCTGTAATGTTAAAAC ATT , FAM-AAAAGCATATGTTATCTGTAATGTTAAAAC ATT , or FAM-AAAAGCATATGTTATCTGTAATGTTAAAAC ATA) , and 5 nM downstream phospho-modified oligonucleotide (Ph-GGGGAATTACTGTTTCTAAACCTAAATTAAT) were added together in a 20 µl reaction ( Fig. 1 ); the phospho-modification is necessary for ligation to occur. The ligation assay was performed using an initial 2 min denaturation at 94°C followed by 20 cycles at 94°C for 30 sec and 45°C for 3 min and a final denaturation of 10 min at 98°C. Only probes that matched to the target were ligated, resulting in a 60 nt HEX-labeled oligonucleotide for the W21 coding sequence, and in a 64 nt FAM labeled oligonucleotide for the R21 coding sequences ( Fig. 1 ). Two microliters of a 1/10 dilution of the OLA products was mixed with 7.5 µl of deionized formamide and 0.5 µl of ROX-1000 size marker (PE Biosystems). The mixture was denatured at 95°C for 3 min and rapidly cooled on ice prior to analysis by a DNA sequencer (ADNid, France). The FAM and HEX peak heights values were determined by Gene Scan analysis (Applied Biosystems), and the data were analyzed using STR and 2.3.79 (Veterinary Genetics Laboratory, University of California, Davis, CA). The results have been expressed as the ratio of the HEX/FAM peak areas.

Results and Discussion

Validation of the ola assay to estimate the ratio of w21 vs. r21 variants.

Our first aim was to estimate the number of enJSRV proviruses coding the W21 Gag variant relative to the number of wild-type (R21) enJSRV proviruses. We performed a molecular assay based on the oligo ligation assay (OLA) of 41 genomes sampled from 10 sheep breeds and five inbred strains derived from the Pre-Alpes du Sud breed ( Table 1 ). We developed an assay involving a PCR followed by a quantitative OLA that allowed the determination of the ratio of the copy numbers of the R21 and W21 enJSRV gag variants ( Fig. 1 ). The PCR specifically amplifies a 470 bp region of the enJSRV gag gene encompassing the R21/W21 variant position. This specificity was provided by the reverse primer that targeted a segment within a variable region (VR1), which is highly divergent between exJSRV and enJSRV [12] . Four OLA probes were designed: the downstream phospho-oligonucleotide probe was common to the R21 and W21 gag sequences, whereas the three labeled upstream oligonucleotides were specific for the mutations responsible for the R21 and W21 variants ( Fig. 1 ). Ligation only occurred when there was a perfect match between the upstream and downstream oligonucleotides. Labeled ligation products were then identified based on their fluorescent dyes and their sizes: 60 nt for W21 vs. 64 nt for R21 ( Fig. 1 ).

The repeatability of the estimation of the ratio of W21 to R21 variants was tested in two steps. First, the penJS56A1 plasmid [6] containing the W21 variant was diluted to 0%, 20%, 50% and 100% vs . the pJaag101 plasmid containing the R21 variant; for each dilution, a PCR followed by the OLA was then performed twice on two replicates, and two curves (one for each replicate) were obtained by plotting the HEX/FAM peak area ratios vs. the serial dilutions. The two corresponding R-squared values were 0.96 and 0.99, reflecting the very high repeatability of the assay and the good prediction values of the curves (F-statistics and p-values = 10 −6 and 10 −8 , respectively). Thus, the standard curve allowed intrapolation of the W21/R21 ratio for test specimens using the measured HEX/FAM ratio. Second, PCRs were performed on genomic and cDNA samples. Ten amplicons were randomly chosen, and OLAs were performed three times on each amplicon. The W21/R21 ratio was estimated using the previously constructed standard curves ( Fig. 2 ), and the high repeatability of the W21/R21 measurement was confirmed by the non-parametric Friedman test (p-value = 0.41), indicating no significant difference between the triplicate measurements from the same sample. The OLA was then performed once for the 41 genomic samples from the breeds and twice for the others samples; in the latter case, the means of the two measurements were used.

For each sample, W21/R21 measurement was repeated three times. Each dot represents a single measurement. Numbers correspond to the samples listed in Figure 1 . NT1 and NT2 correspond to DNA extracted from two non-tumoral samples.

W21 Gag Variant is Present in the Genomes of Many Ovine Breeds

Our results indicate that the W21/R21 ratios are significantly different between ovine breeds (Kruskall-Wallis test, p = 0.01). This result suggests that the R21 and/or W21 enJSRV copy number varies significantly from breed to breed ( Fig. 3 ). Interestingly, the W21/R21 ratio varies between individuals from the same inbred line (e.g., IL16) ( Fig. 3 ), suggesting ongoing proviral amplification. We determined by Southern blotting that the enJSRV proviral copy number varies between but also within the IL16, 19, 36, 39 and 63 inbred lines (data not shown). Likewise, it was recently shown that enJS65A1 copy number can vary 5-fold between several individuals from Texel [13] . This result implies that the two enJS65A1 copies among the 30 enJSRV copies described in a single Texel individual by Arnaud et al. [10] are not representative of Texel individuals. Thanks to the OLA approach, we are now able to estimate the R21/W21 ratio in a large sample of individuals, and do not restrict our screen to enJS65A1 but consider all enJSRV types coding the W21 Gag mutant.

Individuals are numbered according to Table 1 . The W21/R21 ratios are indicated as percentage.

We then tested the hypothesis that a significant level of W21 Gag could provide a selective advantage for the hosts. Thus, we looked for the presence of W21 gag expression in AECII, the primary target of exJSRV together with Clara cells in the lung.

The W21 Gag Expression Level in Sheep Lung Cells Depends on the Tumoral Status of the Sample

We compared the W21/R21 variant frequencies in DNA extracted from the 15 studied lungs (7 tumoral and 8 non-tumoral tissues) and, when available, i.e., for 12 of the 15 animals, from the DNA from the corresponding in vitro -derived primary AECII (5 tumoral and 7 non-tumoral), established as previously reported [14] . All the tumoral alveolar type II cells harbored the JSRV provirus genome, while the non tumoral cell lines were negative [14] . We first estimated the W21/R21 ratios in the genomic DNA. The W21/R21 ratio varied from 13 to 48%, and the medians from the tumoral (T) and non-tumoral (NT) genomic samples were not significantly different (Wilcoxon test, p-value = 0.8). However, we observed a significant difference when we compared the medians between genomic DNA and cDNA extracted from tumoral and non-tumoral samples ( Fig. 4 ): the median of W21/R21 cDNA (RNA) ratio was significantly lower than the median of W21/R21 genomic copies (DNA) in tumoral samples, whereas such a difference did not exist in non-tumoral samples ( Fig. 4 ). This result indicates that the expression of W21 gag was null or lower in tumoral AECII and lung tissues than in non-tumoral samples. Whether the absence of W21 expression favors in vivo the replication of exJSRV could not be assessed in this study. However, it is known that the site of proviral integration can affect the expression by mechanisms that involve local epigenetic modifications, as described for position effects on the expression of transgenic integrants [15] . Comparing the W21 proviral insertion sites between infected sheep that develop a JSRV-induced lung adenocarcinoma and infected sheep that do not develop this adenocarcinoma would help us to answer to this question.

Two Wilcoxon tests were used to compare the medians of W21/R21 ratios measured in DNA and RNA extracts from non-tumoral (p-value = 0.41, non significant) and tumoral samples (p-value = 0.001, highly significant).

Conclusions

In this study using a rapid, discriminative and quantitative molecular technique, we have shown that the W21/R21 ratio varies between individuals from different breeds. Moreover, our results indicate for the first time that W21 and R21 enJSRV are expressed in normal lung tissues and that W21 is not expressed or is expressed at a low level in tumor-derived AECIIs. Our present study did not demonstrate that the absence of W21 gag RNA (and therefore W21 Gag proteins) was the causal factor in the development of tumoral cells, but this study does provide new insights into the putative protective role of some endogenous retroviruses against infection by their exogenous counterparts.

Acknowledgments

We are grateful to Dr Hung Fan for the penJSRV65A and pJSR21 plasmids. We also thank Dr François Guiguen and Dr Jean-Christophe Natorp for the post mortem collection of tissue samples.

Competing Interests: The authors have declared that no competing interests exist.

Funding: This work was supported by Institut National de la Recherche Agronomique, Ecole Pratique des Hautes Etudes, Agence National Recherche “Genomobile” and Fondation Innovation en Infectiologie. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Javascript disabled: Javascript is disabled in your web browser and this website relies on Javascript to function properly. Please enable Javascript.

• Senior Researcher Primary INRAE Grand Est-Nancy Champenoux, France
• INRA Centre Nancy-Lorraine Champenoux, France
• 1, attr{'data-test-id' : 'Updated-Affiliation-Primary-' + $index()}">Primary

• Publications
• Editorial Contributions

Frontiers In and Loop are registered trade marks of Frontiers Media SA. © Copyright 2007-2024 Frontiers Media SA. All rights reserved - Terms and Conditions

Trichodysplasia spinulosa: a polyomavirus infection specifically targeting follicular keratinocytes in immunocompromised patients

Affiliations.

• 1 Department of Dermatology, Université d'Auvergne, CHU Clermont-Ferrand Hôpital Estaing, 63003, Clermont-Ferrand, France.
• 2 Clermont-Ferrand Université, Université d'Auvergne, INSERM U990, Imagerie Moléculaire et Thérapie Vectorisée, 63000, Clermont-Ferrand, France.
• 3 University of Franche Comté, EA3181, SFR FED 4234, Besançon, France.
• 4 University Hospital, Department of Dermatology, 25030, Besançon, France.
• 5 UMR INRA 1282 ISP, Faculté des Sciences Pharmaceutiques, 37200, Tours, France.
• 6 UMR INRA 1282 ISP, Centre INRA Tours-Nouzilly, 37380, Nouzilly, France.
• 7 Department of Medical Microbiology, Leiden University Medical Center, PO Box 9600, 2300-RC, Leiden, The Netherlands.
• 8 Department of Paediatrics, CHU Clermont-Ferrand Hôpital Estaing, 63003, Clermont-Ferrand, France.
• 9 Department of Pathology, Université d'Auvergne, CHU Clermont-Ferrand Hôpital Estaing, 63003, Clermont-Ferrand, France.
• PMID: 26663358
• DOI: 10.1111/bjd.14346

Trichodysplasia spinulosa (TS) is a rare skin disease, caused by a specific polyomavirus, occurring in immunocompromised patients. The pathophysiological mechanisms of TS are not yet fully understood. By using polymerase chain reaction and skin biopsy immunostaining we report evidence, in a paediatric case, of follicular keratinocytes being the primary target of trichodysplasia spinulosa-associated polyomavirus.

© 2015 British Association of Dermatologists.

Publication types

• Case Reports
• Hair Diseases / pathology
• Hair Diseases / virology
• Hair Follicle / pathology
• Hair Follicle / virology
• Immunocompromised Host
• Immunosuppressive Agents / adverse effects
• Keratinocytes / virology
• Opportunistic Infections / complications*
• Opportunistic Infections / pathology
• Polyomavirus Infections / complications*
• Polyomavirus Infections / pathology
• Skin Diseases, Viral / complications*
• Immunosuppressive Agents